[Drug sensitivity research of XXXX inhibitor on @entity0 stem cells].

@entity0 @entity14160 @entity19 @entity5 @entity2239 @entity3470 @entity26720 @entity5231 @entity1994 @entity3844
OBJECTIVE: To test the antitumor effects of the @entity3470 inhibitor @entity2239 in @entity0 stem cells and total cells in vitro and in vivo. METHODS: In vitro studies, we sorted ESA(+) @entity3844 (+) @entity26720 (-/low) cells as stem cells using flow cytometry from primary @entity0 cells. Apoptosis and the cell cycle distributions of stem cells were examined by flow cytometry. The tumorigenicity of stem cells after treatment was investigated by soft agar colony formation assays. BALB/c @entity19 were injected with stem cells and the different treatments were administered. After necropsy, the expression of @entity14160 , @entity5231 , @entity1994 , and phospho-AKT (Thr308) was analyzed by immunohistochemistry. RESULTS: Treatment with @entity2239 resulted in growth inhibition of all stem cells in a dose-dependent manner. An increase in G0-G1 cell cycle arrest and an increased population of cells in early apoptosis were seen in @entity2239 treatment. In vivo, the volumes of the xenograft @entity5 significantly decreased in @entity2239 alone group compared to control group. CONCLUSIONS: @entity2239 could inhibit the growth of both total @entity0 cells and sorted stem cells in vitro and in vivo.
